Early Detection of Autoimmune Thyroid Heart Disease Via Urinary Exosomal Proteins
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03984006|
Recruitment Status : Recruiting
First Posted : June 12, 2019
Last Update Posted : July 1, 2019
Autoimmune thyroid disease revealed close relationship with heart failure, including the entities of subclinical hyperthyroidism and hypothyroidism. Heart failure is a principal complication of all forms of heart disease. The American College of Cardiology defines HF as a complex clinical syndrome that impairs the ability of the ventricle to fill with or inject blood. In fact, it may be caused by a defect in myocardial contraction, by an impairment in ventricular filling with preserved systolic function ('diastolic HF') or by a combination of both. Earlier detection of probable trend of heart failure in subclinical thyroid diseases is very important in not only Taiwan, Pan-Asia, but all over the aging world. However, it is not currently available.
The investigators will enroll 20 patients with subclinical hyperthyroidism, subclinical hypothyroidism, and collect their urine specimens in outpatient clinic per year.
Prognostic biological markers via this prospective study. The study was designed as prospective pattern, and the investigators will enroll clinical and subclinical thyroid disease with quarterly follow-up, then detect urine exosomal proteins NT-proBNP. The investigators try to find the correlation of outcome with unknown/fresh biomarkers in this study with time-dependent manner.
The investigators hope to find earlier predicting biomarkers for heart dysfunction in autoimmune thyroid disease.
|Condition or disease|
|Thyroid Diseases Heart Failure|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Early Detection of Autoimmune Thyroid Heart Disease Via Urinary Exosomal Proteins.|
|Actual Study Start Date :||June 28, 2019|
|Estimated Primary Completion Date :||May 28, 2020|
|Estimated Study Completion Date :||May 28, 2021|
- Change of serum thyroglobulin level [ Time Frame: Within 12 months ]Comparison to enrollment or between 2 groups
- Change of serum free T4 level [ Time Frame: Within 12 months ]Comparison to enrollment or between 2 groups
- Change of serum TSH level [ Time Frame: Within 12 months ]Comparison to enrollment or between 2 groups
- Change of anti-thyroglobulin level [ Time Frame: Within 12 months ]Comparison to enrollment or between 2 groups
- Urinary exosomal NT-proBNP detection [ Time Frame: Within 12 months ]Comparison to enrollment or between 2 groups
- 2-D Cardiac Doppler ultrasonography evaluation [ Time Frame: Within 12 months ]Comparison to enrollment or between 2 groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03984006
|Contact: CHIH-YUAN WANG, Doctor||+886-2-23123456 ext email@example.com|
|Contact: LI-TING HUANG, Bachelor||+886-2-23123456 ext firstname.lastname@example.org|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 10002|
|Contact: Chih-Yuan Wang, Doctor +886-2-23123456 ext 65371 email@example.com|
|Contact: Li-Ting Huang, Bachelor +886-963571218 firstname.lastname@example.org|
|Principal Investigator: Chih-Yuan Wang, Doctor|
|Principal Investigator:||CHIH-YUAN WANG, Doctor||Department of Internal Medicine, National Taiwan University Hospital|